Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CD3

VIR-5500 PSMA–CD3 T-cell engager shows promise in prostate cancer

VIR-5500 PSMA–CD3 T-cell engager shows promise in prostate cancer

Ben Tran • 6 Mar 2026

Phase Ib trial of pasritamig, a bispecific BiTE, and docetaxel in mCRPC

Phase Ib trial of pasritamig, a bispecific BiTE, and docetaxel in mCRPC

David Wise • 5 Mar 2026

Phase I/Ib trial of ASP2138 monotherapy in CLDN18.2+ advanced solid tumors

Phase I/Ib trial of ASP2138 monotherapy in CLDN18.2+ advanced solid tumors

Kohei Shitara • 10 Nov 2025

Phase I/II trial of BNT142, an mRNA encoded bsAb, in CLDN6+ solid tumors

Phase I/II trial of BNT142, an mRNA encoded bsAb, in CLDN6+ solid tumors

Timothy Yap • 3 Jun 2025

IMC-F106C, a novel PRAME × CD3 ImmTAC, in metastatic cutaneous melanoma

IMC-F106C, a novel PRAME × CD3 ImmTAC, in metastatic cutaneous melanoma

Omid Hamid • 7 Jun 2024

Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and SCLC

Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and SCLC

Martin Wermke • 5 Jul 2023

BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC

BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC

Martin Wermke • 23 Jun 2023

Update from a phase 1 study of AMG 757 in SCLC

Update from a phase 1 study of AMG 757 in SCLC

Sanjay Popat • 12 Apr 2021

CAR-T for Ewing’s sarcoma: impacts of the tumor microenvironment

CAR-T for Ewing’s sarcoma: impacts of the tumor microenvironment

Rimas J. Orentas • 10 Apr 2021

What's next for next for NETs: novel targeted therapies for neuroendrocrine tumors

What's next for next for NETs: novel targeted therapies for neuroendrocrine tumors

Rocio Garcia-Carbonero • 18 Jan 2019

Cancer pathology: adapting to and advancing with immunotherapy

Cancer pathology: adapting to and advancing with immunotherapy

Manuel Salto-Tellez • 26 Nov 2018